Results 31 to 40 of about 7,232 (251)

Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial

Critical Care Explorations, 2021
Objectives:. Our preliminary data and observational studies suggested an increasing “off label” use of oral midodrine as a vasopressor sparing agent in various groups of critically ill patients, including those with sepsis.
Amos Lal, MBBS, FACP, Vrinda Trivedi, MBBS, Mahrukh S. Rizvi, MD, Amy Amsbaugh, RRT, LRT, Melissa K Myers, MD, Khaled Saleh, MD, Rahul Kashyap, MBBS, MBA, Ognjen Gajic, MD, MSc, FCCP, FCCM   +7 more
doaj   +1 more source

Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery. [PDF]

Geriatr Gerontol Int
Geriatrics &Gerontology International, Volume 25, Issue 12, Page 1962-1964, December 2025.
De Louche CD, Palliyage S.
europepmc   +2 more sources

Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]

JGH Open
ABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ, Reddy KR, Brown KA, Landis CS, Cullaro G, Huang X, Kelkar SS, Raina R, Corman S, Kebede N, Edmundson P, Jamil K, Allegretti AS.   +12 more
europepmc   +2 more sources

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

Frontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud, Doaa H Abdelaziz, Doaa H Abdelaziz, Sherief Abd-Elsalam, Noha O. Mansour   +4 more
doaj   +1 more source

Systematic differences between Cochrane and non-Cochrane meta-analyses on the same topic: a matched pair analysis [PDF]

, 2015
BACKGROUND: Meta-analyses conducted via the Cochrane Collaboration adhere to strict methodological and reporting standards aiming to minimize bias, maximize transparency/reproducibility, and improve the accuracy of summarized data.
Ameli, Omid, Brennan, Alana, Gill, Christopher J., LaValley, Michael, Reinen, Nichole, Useem, Johanna, Vickery, Michelle   +6 more
core   +4 more sources

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P, Arroyo V, BERNARDI, MAURO, Blendis L, Di Bona G, Garcia Tsao G, Gerbes A, Ginès P, Guevara M, Gülberg V, Henriksen JH, Kamath P, Lee S, Moore K, Moreau R, Mullen K, Ortega R, Ruiz del Arbol L, Salerno F, Sanyal A, Terg R., Wong F   +21 more
core   +4 more sources

Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study

Annals of Intensive Care, 2020
Background Persistent hypotension is a frequent complication after cardiac surgery with cardiopulmonary bypass (CPB). Midodrine, an orally administered alpha agonist, could potentially reduce intravenous vasopressor use and accelerate ICU discharge of ...
Jan-Alexis Tremblay, Philippe Laramée, Yoan Lamarche, André Denault, William Beaubien-Souligny, Anne-Julie Frenette, Loay Kontar, Karim Serri, Emmanuel Charbonney   +8 more
doaj   +1 more source

It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide [PDF]

, 2016
A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;
Kane, William
core   +2 more sources

Effect of Oral Vasopressors Used for Liberation from Intravenous Vasopressors in Intensive Care Unit Patients Recovering from Spinal Shock: A Randomized Controlled Trial

Critical Care Research and Practice, 2022
Background. Early vasopressor utilization has been associated with improved outcomes of patients with spinal shock; however, there are difficulties in weaning off vasopressors, in which patients after recovery from spinal shock develop a state of ...
Ahmed Talaat Ahmed Ali, Mervat Anwar Abd EL-Aziz, Ahmed Mohamed Abdelhafez, Amr Mohamed Ahmed Thabet   +3 more
doaj   +1 more source

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 [PDF]

, 2017
Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
Alessandria, Angeli, Arroyo, Belcher, Belcher, Besso, Boyer, Cavallin, Fernández, Gillies, Gluud, Hadengue, Mandal, Marik, Martin-Llahi, Martin-Llahi, Mattos, Moher, Navasa, Neri, Newby, Platt, Ruiz-del-Arbol, Salerno, Salerno, Salmeron, Sanyal, Schepke, Sharma, Silawat, Singh, Solanki, Srivastava, Tavakkoli, Wood   +34 more
core   +3 more sources